[学术机构可以改善对CAR-T细胞的获取吗?]
Camille Le Guen1, Audrey Grain2, Baptiste Le Calvez3
1Unité de thérapie cellulaire et génique, CHU de Nantes, 44093 Nantes, France.
Bulletin du cancer
|November 29, 2023
概括
法国的学术机构可以通过克服其生产中的经济和生态挑战,改善获得仿真抗原受体T淋巴细胞 (CAR-T细胞) 的机会. 这涉及在学术环境中建立可行的CAR-T细胞制造工艺.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 生物技术是生物技术.
背景情况:
- 化学抗原受体T淋巴细胞 (CAR-T细胞) 是对癌症治疗至关重要的先进疗法药物.
- 目前的CAR-T电池生产主要由工业公司处理,这导致了高成本和漫长的交货时间.
- 法国医院细胞疗法单位尚未获准用于常规的学术CAR-T细胞生产.
研究的目的:
- 探索在法国的学术结构中建立CAR-T细胞生产的可行性.
- 为应对与CAR-T细胞制造相关的经济和生态挑战.
- 为了改善患者获得CAR-T细胞治疗的机会.
主要方法:
- 该研究概述了建立学术CAR-T细胞生产所需的要素和专业知识.
- 它强调病毒转导 (lentiviral或逆病毒) 是一种常见的基因改造方法.
- 强调了良好的制造实践 (GMP) 级病毒载体的关键作用.
主要成果:
- GMP级病毒载体的高成本被认为是CAR-T细胞发育的主要限制因素.
- 工业CAR-T细胞生产成本约为每次注射35万欧元,交付时间为3-5周.
- 学术生产可能会降低成本并提高可访问性.
结论:
- 建立学术CAR-T细胞生产需要大量的科学和技术专业知识.
- 克服病毒载体的成本和满足制药质量体系标准是关键的挑战.
- 成功实施可以提高患者对CAR-T细胞的可访问性.
相关概念视频
01:22T Cell Activation and Clonal Selection
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.